Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | ACHE | P22303 | 1/20 | 0.69 |
| ▸ | RAD52 | P43351 | 1/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956510 | 0.98 | HRH3 (0.72) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL1986256 | 0.91 | PSMB1 (0.70) | HRH3 | |
| SCHEMBL4416554 | 0.91 | PSMB1 (0.70) | HRH3 | |
| SCHEMBL3581930 | 0.91 | HRH3 (0.89) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL1986761 | 0.89 | PSMB1 (0.67) | HRH3 | |
| SCHEMBL3578646 | 0.87 | HRH3 (0.90) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL2819860 | 0.87 | HRH3 (0.77) | HRH3KCNH2ACHERAD52 | |
| SCHEMBL4094339 | 0.86 | HRH3 (1.00) | HRH3KCNH2HRH1 | |
| SCHEMBL12050645 | 0.86 | HRH3 (1.00) | HRH3KCNH2HRH1 | |
| SCHEMBL7945866 | 0.85 | RAB9A (0.66) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007735-B1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20080039444-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039444-A1 | COMPOUNDS | CMA1, MRGPRX2, HRH2 | HRH3 16/4885KCNH2 1588/4885ACHE 1108/4885 |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | HRH2, HRH3, HRH4 | HRH3 2/4885KCNH2 112/4885ACHE 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.